News

As part of the transaction, Emergent acquired Avanir’s lead candidate (AVP-21D9) along with several additional anthrax antibodies. In addition, Emergent also received a limited exclusive license to use

Solagran’s manufacturing partner Galenopharm is now free to commence production of Ropren for sale throughout Russia. Solagran is hopeful that initial production volumes will be sufficient to meet

Under terms of the agreement, the companies will evenly divide the value of the joint venture. Abbott receives rights to the oncology treatment, Lupron, including the commercial organization

Abioklad is used for the treatment of cancer malignancy-associated hypercalcemia (high blood calcium), the inhibition of osteolysis (degeneration of bone tissue), and the decrease of bone pain associated

Since joining 3SBio in June 2007, Dr Chen has been responsible for developing long-range growth strategies and pursuing strategic business opportunities and external alliances with biotechnology and pharmaceutical

Targeted Molecular Diagnostics (TMD) has formulated a proprietary solution of broad-spectrum phosphatase inhibitors in the PhosphoGuard kit which has been used in several Phase II and III oncology

In addition, Guidant Investment has granted to the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock to cover over-allotments, if any.

Cyanokit was approved by the Japanese Ministry of Health in November 2007, for the treatment of cyanide intoxication caused by hydrocyanic acid and its derivatives in both adults

Series A investor Sofinnova Partners also participated in the B round. Aelios Finance served as financial advisor to Stentys. Brian Kerr, one of the founding directors of Scottish